Unknown PHASE2 INTERVENTIONAL 1-arm NCT05812534

Study of Cadonilimab Combined With Bevacizumab and Chemotherapy for Advanced Nonsquamous Non-small Cell Lung Cancer Patients With Untreated Brain Metastases (CBC)

Phase II Study of Cadonilimab Combined With Bevacizumab and Chemotherapy for Advanced Nonsquamous Non-small Cell Lung Cancer Patients With Untreated Brain Metastases

Sponsor: Fujian Cancer Hospital

Conditions Brain Metastases Non Small Cell Lung Cancer

Interventions Cadonilimab

Updated 6 times since 2023 Last updated: Nov 16, 2023 Started: Dec 31, 2023 Primary completion: Jun 30, 2024 Completion: Jun 30, 2025

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Brain Metastases and Non Small Cell Lung Cancer, this trial is ongoing. The trial is conducted by Fujian Cancer Hospital and has accumulated 6 data snapshots since 2023. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

6 versions recorded

Jan 2026 — Present [monthly]

Unknown PHASE2

Status: Not Yet Recruiting → Unknown
Sep 2024 — Jan 2026 [monthly]

Not Yet Recruiting PHASE2
Jul 2024 — Sep 2024 [monthly]

Not Yet Recruiting PHASE2
Dec 2023 — Jul 2024 [monthly]

Not Yet Recruiting PHASE2
Jun 2023 — Dec 2023 [monthly]

Not Yet Recruiting PHASE2

▶ Show 1 earlier version

May 2023 — Jun 2023 [monthly]

Not Yet Recruiting PHASE2

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Fujian Cancer Hospital
Hunan Cancer Hospital
Second Affiliated Hospital of Nanchang University

Data source: Second Affiliated Hospital of Nanchang University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.